Brielle Benyon

Early Intervention For Neurotoxicity Can Improve Outcomes With Cilta-Cel in Relapsed/Refractory Multiple Myeloma

June 13th 2021

Neurologic adverse effect associated with CAR T-cell therapies like ciltacabtagene autoleucel can be managed without long-term lasting effects, as long as they are caught and treated promptly in patients with relapsed/refractory multiple myeloma.

Subcutaneous Elranatamab Elicits Encouraging Responses in Relapsed/Refractory Myeloma

June 8th 2021

The BCMA-targeting humanized bispecific monoclonal antibody elranatamab elicited high response rates when subcutaneously delivered at higher doses in patients with relapsed/refractory multiple myeloma.

Acalabrutinib is Better Tolerated, Noninferior to Ibrutinib in Previously Treated CLL

June 7th 2021

Larotrectinib Demonstrates Promising Responses in NTRK-Fusion+ CNS Tumors

June 7th 2021

Larotrectinib has demonstrated efficacious responses and disease control in patients with TRK fusion–positive central nervous system tumors.

Frontline Nivolumab Plus Ipilimumab or Chemo Improves Survival Outcomes in Advanced ESCC

June 3rd 2021

The addition of nivolumab to either ipilimumab or chemotherapy resulted in improved survival outcomes vs chemotherapy alone in the frontline treatment of patients with unresectable advanced or metastatic esophageal squamous cell carcinoma.

Eganelisib Could Enhance Responses With Nivolumab in Urothelial Carcinoma

February 11th 2021

February 11, 2021 - Eganelisib, a novel PI3K-y inhibitor, demonstrated higher responses rates with nivolumab in patients with metastatic urothelial carcinoma.

Virtual Prehabilitation Improves Activity Level, Exercise Capacity Prior to Lung Cancer Surgery

February 2nd 2021

February 2, 2021 - Virtual prehabilitation could potentially improve physical activity level and exercise capacity in patients with lung cancer before they undergo surgery for their disease.

Mutations, irAEs May Help Predict Immunotherapy Response in NSCLC

January 28th 2021

January 28, 2021- Patients with non-small cell lung cancer who experience immune-related adverse events may have better survival outcomes than those without.

AI-Based Tool May Help Patients Find GI Cancer Clinical Trials

January 15th 2021

January 15, 2021 - A novel artificial intelligence-based search tool made it easier for patients to find and understand cancer clinical trials, while also offering more clarity on how to enroll in them

Groundbreaking Breast Cancer Researcher Shares a World of Knowledge

January 14th 2021

Young Hope Rugo saved up her S&H Green Stamps to buy a children’s chemistry set from a Sears catalog. At the age of 8, Rugo knew she wanted to be a scientist.

Weekly Dose-Dense Chemotherapy Not Superior to Standard of Care in Epithelial Ovarian Cancer

September 21st 2020

Weekly dose-dense chemotherapy is not superior to standard 3 weekly chemotherapy for patients with epithelial ovarian cancer when it comes to progression-free survival and overall survival, though the regimen is safe and effective.

Genetic Counselor Addresses Common Questions About Testing in Oncology

August 1st 2020

Genetic testing is more important now than ever before, as biomarker-driven cancer treatments continue to receive approval across many tumor types.

Teclistamab Appears Safe at All Doses for Relapsed/Refractory Myeloma Treatment

May 31st 2020

Teclistamab (JNJ-64007957) appeared to be a safe and efficacious treatment for patients with relapsed/refractory multiple myeloma.

Zanubrutinib Shows Clinical Activity, Tolerability in Waldenstrom Macroglobulinemia

May 29th 2020

Zanubrutinib demonstrated a higher complete response or very good partial response rate compared with ibrutinib in patients with Waldenström macroglobulinemia, although the findings were not found to be statistically significant.

Lower-Dose Chemotherapy Regimen Benefits Elderly, Frail Patients with Gastroesophageal Cancer

May 16th 2019

A lower dose of oxaliplatin and capecitabine had comparable efficacy and minimized adverse events in elderly and frail patients with advanced gastroesophageal cancer.

Younger Patients With CRC Misdiagnosed, Diagnosed at Later Stages

February 28th 2019

Many younger patients see more than one doctor and face misdiagnoses before being given a diagnosis of colorectal cancer.

Telephone-Based Lifestyle Interventions Improved Breast Cancer Outcomes

December 8th 2018

Early-stage breast cancer survivors who completed a telephone-based lifestyle intervention program lost weight and tended to have higher rates of disease-free survival.